DrugPatentWatch Database Preview
AMARIN Company Profile
» See Plans and Pricing
What is the competitive landscape for AMARIN, and what generic alternatives to AMARIN drugs are available?
AMARIN has two approved drugs.
There are fifty-nine US patents protecting AMARIN drugs.
There are two hundred and sixty-one patent family members on AMARIN drugs in fifty-one countries and two supplementary protection certificates in one country.
Summary for AMARIN
| International Patents: | 261 |
| US Patents: | 59 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for AMARIN: | See patent lawsuits for AMARIN |
Drugs and US Patents for AMARIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | AB | RX | Yes | No | 8,415,335 | Start Trial | Start Trial | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,377,920 | Start Trial | Start Trial | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | AB | RX | Yes | No | 8,623,406 | Start Trial | Start Trial | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | AB | RX | Yes | No | 10,383,840 | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AMARIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | 8,188,146 | Start Trial |
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | 8,188,146 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AMARIN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 1 g | ➤ Subscribe | 2013-01-15 |
| ➤ Subscribe | Capsules | 500 mg | ➤ Subscribe | 2017-08-29 |
| ➤ Subscribe | Capsules | 1 g | ➤ Subscribe | 2016-07-26 |
International Patents for AMARIN Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | WO2007142118 | Start Trial |
| European Patent Office | 2777701 | Start Trial |
| Chile | 2014003534 | Start Trial |
| Philippines | 12015500407 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AMARIN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0253738 | 96C0009 | Belgium | Start Trial | PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION: |
| 0113964 | 97C0037 | Belgium | Start Trial | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
